Joshua Barzilay | Clinical Neuroscience | Best Researcher Award

Published on by Neuroscientists

Dr. Joshua Barzilay | Clinical Neuroscience | Best Researcher Award

Kaiser Permanente of Georgia, Emory School of Medicine | United States

Dr. Joshua I. Barzilay is a senior clinician–scientist and board-certified endocrinologist whose research spans diabetes, hypertension, cardiovascular disease, metabolic syndrome, and aging, integrating epidemiology with long-term clinical outcomes. His early work included oncology and hematology research, followed by a sustained focus on endocrine and metabolic disorders during his tenure at Kaiser Permanente of Georgia and Emory University School of Medicine. Dr. Barzilay has made influential contributions to large, multicenter clinical and population-based studies, including ALLHAT, ACCORD/ACCORDION, and the Cardiovascular Health Study, where he has served on steering committees and specialty working groups. His research has clarified the impact of glucose dysregulation, insulin resistance, and antihypertensive therapies on cardiovascular morbidity, mortality, and incident diabetes, particularly in older adults. A major theme of his work is the relationship between metabolic syndrome, frailty, autonomic function, and cardiovascular risk, providing evidence to guide treatment strategies in complex patients. In addition to his research, Dr. Barzilay has played a key role in national diabetes and hypertension guideline development, medical education, and dissemination of evidence-based care, shaping clinical practice across endocrinology and primary care.

Citation Metrics (Scopus)

25000
20000
15000
10000
0

Citations
24,155

Documents
186
h-index
58

Citations

Documents

h-index


View Scopus Profile
 View Google Scholar Profile

Featured Publications

Hui Zhang | Clinical Neuroscience | Best Researcher Award

Published on by Neuroscientists

Prof. Hui Zhang | Clinical Neuroscience | Best Researcher Award

Prof. Hui Zhang | Northwestern University | United States

Hui Zhang is a Professor in the Division of Biostatistics, Department of Preventive Medicine at Northwestern University Feinberg School of Medicine, where he also holds appointments at the Robert H. Lurie Comprehensive Cancer Center, the Mesulam Center for Cognitive Neurology and Alzheimer’s Disease, and the Center for Epidemiology and Population Health. he serves as Director of the Northwestern Brain Tumor SPORE Biostatistics and Bioinformatics Core and leads the Biostatistics and Data Management Core at the Mesulam Center. With a Ph.D. in Statistics from the University of Rochester, her academic foundation spans pharmacology, neurophysiology, and biology, reflecting her interdisciplinary expertise in biostatistics and biomedical research. His previous experience includes research roles at St. Jude Children’s Research Hospital, where she contributed significantly to clinical and statistical protocol development. Professor Zhang’s work focuses on statistical methodologies for cancer and neurological disease research, data integration, and bioinformatics applications. he is an active member of several professional societies, including the American Statistical Association and the International Chinese Statistical Association. A highly cited researcher, she has accumulated over 11,422 citations, an h-index of 43, and an i10-index of 100, demonstrating her substantial impact and leadership in the fields of biostatistics and medical data science.

Profile: Google Scholar

Featured Publications

Moss, A. J., Hall, W. J., Cannom, D. S., Klein, H., Brown, M. W., Daubert, J. P., et al. (2009). Cardiac-resynchronization therapy for the prevention of heart-failure events. New England Journal of Medicine, 361(14), 1329–1338.

Gunzler, D., Chen, T., Wu, P., & Zhang, H. (2013). Introduction to mediation analysis with structural equation modeling. Shanghai Archives of Psychiatry, 25(6), 390–394.

Wan, T., Jun, H. U., Pan, W. U., & Hua, H. E. (2015). Kappa coefficient: A popular measure of rater agreement. Shanghai Archives of Psychiatry, 27(1), 62–67.

Pu, J., Wang, S., Yin, Y., Zhang, G., Carter, R. A., Wang, J., Xu, G., Sun, H., Wang, M., et al. (2015). Evolution of the H9N2 influenza genotype that facilitated the genesis of the novel H7N9 virus. Proceedings of the National Academy of Sciences, 112(2), 548–553.

Guy, C. S., Vignali, K. M., Temirov, J., Bettini, M. L., Overacre, A. E., Smeltzer, M., et al. (2013). Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nature Immunology, 14(3), 262–270.

Shen, S., Chen, X., Cai, J., Yu, J., Gao, J., Hu, S., Zhai, X., Liang, C., Ju, X., Jiang, H., et al. (2020). Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome–positive acute lymphoblastic leukemia: A randomized clinical trial. JAMA Oncology, 6(3), 358–366.

Sonabend, A. M., Gould, A., Amidei, C., Ward, R., Schmidt, K. A., Zhang, D. Y., et al. (2023). Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: A phase 1 trial. The Lancet Oncology, 24(5), 509–522.

William Blumentals | Clinical Neuroscience | Excellence in Research Award

Published on by Neuroscientists

Dr. William Blumentals | Clinical Neuroscience | Excellence in Research Award

Dr. William Blumentals | Sanofi | United States

Dr. William A. Blumentals is an accomplished epidemiologist and pharmaceutical executive recognized for his leadership in pharmacoepidemiology, real-world evidence generation, and global health outcomes research. He serves as Associate Vice President and Head of Specialty Care Pharmacoepidemiology at Sanofi in Cambridge, Massachusetts, where he oversees a multinational team of epidemiologists across the United States and Europe, driving innovation in inflammation, immunology, oncology, and rare disease research. With a Ph.D. in Epidemiology from the University of South Florida, along with advanced degrees in Statistics, Epidemiology, and Biology, Dr. Blumentals has held senior positions at leading organizations including Shire Pharmaceuticals, Shionogi Inc., and Hoffmann-La Roche. His expertise spans strategic development of large-scale observational studies, organizational leadership, and cross-functional collaboration to optimize evidence-based decision-making in healthcare. As a thought leader in real-world evidence and outcomes research, he has contributed significantly to advancing global epidemiological practices. Dr. Blumentals has authored 36 scientific documents, accumulated 1,594 citations from 1,463 documents, and holds an h-index of 23, reflecting his strong scientific influence and impact in epidemiology and pharmaceutical research.

Profile: Scopus

Featured Publications

Multiple sclerosis and the association with inflammatory bowel disease: Results from a retrospective cohort study. (2025). Multiple Sclerosis and Related Disorders.


Cytokine release syndrome risk model with T-cell engaging therapies. (2025). Cytotherapy.


Evaluating the accuracy of responses by large language models for information on disease epidemiology. (2025). Pharmacoepidemiology and Drug Safety.

Calixto Machado | Clinical Neuroscience | Best Researcher Award

Published on by Neuroscientists

Prof. Dr. Calixto Machado | Clinical Neuroscience | Best Researcher Award

Prof. Dr. Calixto Machado | Institute of Neurology and Neurosurgery | Cuba

Calixto Machado is a Full Professor and Senior Researcher in Neurology and Clinical Neurophysiology at the Institute of Neurology and Neurosurgery in Havana, Cuba, and a Corresponding Fellow of the American Academy of Neurology. He completed his medical degree, followed by specialist training in neurology and clinical neurophysiology, and then earned his PhD. Over four decades he has led pioneering research on disorders of consciousness, brain death, stroke, autism, autonomic nervous system disorders and the neurological sequelae of SARS-CoV-2. He has published nearly 700 peer-reviewed journal articles, book chapters and authored seven books; his work is recognised internationally through numerous symposia and awards. His Google Scholar profile lists an h-index of 37, and over 24 000 citations across his published documents.

Profile: Google Scholar

Featured Publications:

Machado, C. (2025, September 9). Jahi McMath case: A comprehensive and updated narrative. World Journal of Critical Care Medicine, 14(3), 107513.

Machado, C. (2022). The Jahi McMath case: First detailed study of her brain. Neurology India, 70(5), 22–35.

Giacino, J. T., Ashwal, S., Childs, N., Cranford, R., Jennett, B., Katz, D. I., Kelly, J. P., & others. (2002). The minimally conscious state: Definition and diagnostic criteria. Neurology, 58(3), 349–353.

Sloan, M. A., Alexandrov, A. V., Tegeler, C. H., Spencer, M. P., Caplan, L. R., & others. (2004). Assessment: Transcranial Doppler ultrasonography report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 62(9), 1468–1481.

Machado, C. (2002). Brain death worldwide: Accepted fact but no global consensus in diagnostic criteria. Neurology.

Machado, C. (2007). Cerebral response to patient’s own name in the vegetative and minimally conscious states. Neurology, 69(7), 708.

Machado, C., Korein, J., Ferrer, Y., Portela, L., & others. (2007). The concept of brain death did not evolve to benefit organ transplants. Journal of Medical Ethics, 33, 197–200.

Machado, C. (2007). The concept of brain death did not evolve to benefit organ transplants. In C. Machado (Ed.), Brain death: A reappraisal (pp. 1–20). Springer.

Machado, C. (2007). Brain death: A reappraisal. Springer Science & Business Media.

Machado, C. (2007). The first organ transplant from a brain-dead donor. In C. Machado (Ed.), Brain death: A reappraisal (pp. 1–20). Springer.

Machado, C. (2010). Diagnosis of brain death. Neurology International, 2(1), e2.

Graf, W. D., Miller, G., Epstein, L. G., & Rapin, I. (2017). The autism “epidemic”: Ethical, legal, and social issues in a developmental spectrum disorder. Neurology, 88(14), 1371–1380.

Machado, C., Korein, J., Aubert, E., Bosch, J., Alvarez, M. A., Rodríguez, R., & others. (2007). Recognizing a mother’s voice in the persistent vegetative state. Clinical EEG and Neuroscience, 38(3), 124–126.

Lewis, A., Bernat, J. L., Blosser, S., Bonnie, R. J., Epstein, L. G., Hutchins, J., & others. (2018). An interdisciplinary response to contemporary concerns about brain death determination. Neurology, 90(9), 423–426.*

Seyyed Ali Zendehbad | Clinical Neuroscience | Best Researcher Award

Published on by Neuroscientists

Dr. Seyyed Ali Zendehbad | Clinical Neuroscience | Best Researcher Award

Dr. Seyyed Ali | Zendehbad University of Mazandaran | Iran

Dr. Seyyed Ali Zendehbad is a multidisciplinary researcher specializing in biomedical signal processing, cognitive computational neuroscience, and neurorehabilitation technologies. His research integrates deep learning, pattern recognition, and multimodal biological data modeling to enhance fatigue detection and neurorehabilitation systems. He has authored several peer-reviewed papers in reputable journals such as Scientific Reports, IEEE Access, Sensing and Bio-Sensing Research, and Healthcare Technology Letters, focusing on hybrid AI frameworks, EMG signal processing, and muscle synergy-based biofeedback mechanisms. Dr. Zendehbad’s work on developing intelligent rehabilitation systems, including his models like TraxVBF and FatigueNet, contributes to advancing telemonitoring and assistive technologies for neurological recovery. His scholarly output includes more than 25 documents, over 600 citations, and an h-index of 12, reflecting his growing impact in computational neuroscience and biomedical engineering. Recognized for innovation, he has achieved first-place awards in multiple national startup competitions and was honored with the Best Poster Award at the Congress of Neurology and Clinical Electrophysiology of Iran. As a postdoctoral researcher at the University of Mazandaran, his ongoing work emphasizes integrating trustworthy AI into telehealth systems, promoting equitable and efficient digital healthcare delivery through interdisciplinary research and technological innovation.

Profile: Orcid

Featured Publications

1. Mazrooei Rad, E., Mazinani, S. M., & Zendehbad, S. A. (2025). Diagnosis of Alzheimer’s disease using non-linear features of ERP signals through a hybrid attention-based CNN-LSTM model. Computer Methods and Programs in Biomedicine Update, 5, 100192.

2. Zendehbad, S. A., Sharifi Razavi, A., Tabrizi, N., & Sedaghat, Z. (2025). A systematic review of artificial intelligence techniques based on electroencephalography analysis in the diagnosis of epilepsy disorders: A clinical perspective. Epilepsy Research, 207, 107582.

3. Mazrooei Rad, E., Zendehbad, S. A., & Hosseinzadeh, V. (2025). Fetal QRS complex detection based on adaptive filters and peak detection. Research on Biomedical Engineering, 41(3), 424–438.

4. Zendehbad, S. A., Ghasemi, J., & Samsami Khodadad, F. (2025). FatigueNet: A hybrid graph neural network and transformer framework for real-time multimodal fatigue detection. Scientific Reports, 15(1), 640.

5. Safdel, A., Zendehbad, S. A., & Ghasemi, J. (2025). Advanced deep learning approaches for accurate and efficient suspicious behavior detection in surveillance videos. Computational Sciences and Engineering, 21(2), 1099.

Maria -Camelia Stancioaica | Clinical Neuroscience |

Published on by Neuroscientists

Ms. Maria -Camelia Stancioaica | Clinical Neuroscience | Best Researcher Award

Ms. Maria -Camelia Stancioaica | Fundeni Clinical Hospital | Romania

Dr. Maria Camelia Stăncioaica is a dedicated Romanian hematologist affiliated with the Fundeni Clinical Institute in Bucharest, where she serves as the Acute Leukemia Program Coordinator. She holds an M.D. in Clinical Hematology and is currently pursuing her Ph.D. at the Carol Davila University of Medicine. Her professional development includes international experience through observership at Johns Hopkins Hospital in the USA and an internship at Pitié–Salpêtrière Hospital in France. Dr. Stăncioaica has contributed to advancing hematologic research through publications addressing acute leukemia, fungal infections in immunocompromised patients, and targeted therapies in acute myeloid leukemia. Her notable works include studies on FLT3 inhibitors, differentiation syndrome in pregnancy, and invasive fusariosis outbreaks. Actively engaged in global scientific dialogue, she has been a speaker and session chair at prominent hematology conferences across Europe. She also participates in several clinical trials as both principal and subinvestigator, focusing on novel therapeutic strategies in leukemia management. Dr. Stăncioaica’s research achievements are reflected in her 21 citations, 2 h-index, and 1 i10-index, underscoring her growing influence in clinical hematology. She is a member of the European Hematology Association and the Romanian Society of Hematology, contributing to both national and international medical communities.

Profile: Google Scholar

Featured Publications

1. Ghiaur, A., Doran, C., Gaman, M. A., Ionescu, B., Tatic, A., Cirstea, M., … Stancioaica, M. C. (2024). Acute promyelocytic leukemia: Review of complications related to all-trans retinoic acid and arsenic trioxide therapy. Cancers, 16(6), 1160.

2. Mohorea‐Neata, A. L., Ghita, M. C., Moroti, R., Ghiaur, A., Ionescu, B., Tatic, A., … Stancioaica, M. C. (2023). Invasive fusariosis in acute leukaemia patients—An outbreak in the haematology ward. Mycoses, 66(8), 705–710.

3. Droc, G., Stancioaica, M. C., Soare, C. G., Stefan, M. G., Ingustu, D., Martac, C., … Ghiaur, A. (2023). Acute promyelocytic leukemia and severe differentiation syndrome in pregnancy—A management challenge. Life, 13(5), 1141.

4. Coriu, D., & Stancioaica, M. C. (2023). Moving low-risk myelodysplastic syndromes from humans to mice: Is it truly that simple? Haematologica, 109(1), 8.

5. Stancioaica, M. C., Coriu, D., & Ghiaur, G. (2025). FLT3: A 35-year voyage from discovery to the next generation of targeted therapy in AML. Cancers.

Jane Paulsen | Clinical Neuroscience | Best Researcher Award

Published on by Neuroscientists

Prof. Dr. Jane Paulsen | Clinical Neuroscience | Best Researcher Award

Prof. Dr. Jane Paulsen | University of Wisconsin Madison | United States

Dr. Jane S. Paulsen, Ph.D., is a Professor of Neurology and Vice Chair for Research at the University of Wisconsin–Madison, where she also contributes to the Department of Neurosciences Graduate Program. Her expertise lies in cognitive, psychiatric, and imaging correlates of neuropsychiatric disorders, with a strong focus on the early detection of brain diseases and the development of innovative methods for clinical trials. She has significantly advanced the understanding of genetic discrimination and the discovery and validation of biological and clinical markers of brain disease, incorporating neuroimaging and omics-based outcomes into her research. Dr. Paulsen completed her Ph.D. in Counseling Psychology at the University of Iowa, followed by postdoctoral training in Neuropsychology at the University of California, San Diego, where she worked on Alzheimer’s and geriatric psychiatry research. Over her career, she has held key positions including Director of the Huntington’s Disease Clinical Research Program at UCSD and has contributed extensively to advancing neuropsychological research and clinical applications. Her scholarly impact includes 4 published documents, 78 citations from 77 documents, and an h-index of 3, reflecting her influence in the fields of neurology, neuropsychology, and cognitive neuroscience.

Profiles: Scopus | Google Scholar | Reserach Gate | linked In

Featured Publications

Sachdev, P. S., Blacker, D., Blazer, D. G., Ganguli, M., Jeste, D. V., Paulsen, J. S., & Petersen, R. C. (2014). Classifying neurocognitive disorders: The DSM-5 approach. Nature Reviews Neurology, 10(11), 634–642.

Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., & Paulsen, J. S. (2014). Huntington disease: Natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology, 10(4), 204–216.

Paulsen, J. S., Langbehn, D. R., Stout, J. C., Aylward, E., Ross, C. A., Nance, M., & Shoulson, I. (2008). Detection of Huntington’s disease decades before diagnosis: The Predict-HD study. Journal of Neurology, Neurosurgery & Psychiatry, 79(8), 874–880.

Langbehn, D. R., Brinkman, R. R., Falush, D., Paulsen, J. S., Hayden, M. R., & International Huntington’s Disease Collaborative Group. (2004). A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clinical Genetics, 65(4), 267–277.

Levy, M. L., Cummings, J. L., Fairbanks, L. A., Masterman, D., Miller, B. L., Craig, A. H., & Paulsen, J. S. (1998). Apathy is not depression. The Journal of Neuropsychiatry and Clinical Neurosciences, 10(3), 314–319.

Sachdev, P., Kalaria, R., O’Brien, J., Skoog, I., Alladi, S., Black, S. E., Blacker, D., & Paulsen, J. S. (2014). Diagnostic criteria for vascular cognitive disorders: A VASCOG statement. Alzheimer Disease & Associated Disorders, 28(3), 206–218.

Palmer, B. W., Heaton, R. K., Paulsen, J. S., Kuck, J., Braff, D., Harris, M. J., & Zisook, S. (1997). Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology, 11(3), 437–446.

Plis, S. M., Hjelm, D. R., Salakhutdinov, R., Allen, E. A., Bockholt, H. J., Long, J. D., & Calhoun, V. D. (2014). Deep learning for neuroimaging: A validation study. Frontiers in Neuroscience, 8, 229.

Mohamed, S., Paulsen, J. S., O’Leary, D., Arndt, S., & Andreasen, N. (1999). Generalized cognitive deficits in schizophrenia: A study of first-episode patients. Archives of General Psychiatry, 56(8), 749–754.

Paulsen, J. S., Ready, R. E., Hamilton, J. M., Mega, M. S., & Cummings, J. L. (2001). Neuropsychiatric aspects of Huntington’s disease. Journal of Neurology, Neurosurgery & Psychiatry, 71(3), 310–314.

Chahra Chbili | Clinical Neuroscience | Best Researcher Award

Published on by Neuroscientists

Assist. Prof. Dr. Chahra Chbili | Clinical Neuroscience | Best Researcher Award

Assist. Prof. Dr. Chahra Chbili | University of Sousse | Tunisia

Dr. Chahra Chbili is an Assistant Professor of Pharmacology at the Higher School of Health Sciences and Techniques of Sousse (ESSTSS) and a member of the Research Laboratory of Metabolic Biophysics and Applied Pharmacology (LR/12ES02) at the Faculty of Medicine Ibn El Jazzar of Sousse, Tunisia. Her academic journey spans extensive training in biological sciences, genetics, and medical biotechnology, with a Ph.D. earned with highest honors for her work on the pharmacokinetic and pharmacogenetic study of carbamazepine therapy in epileptic and bipolar patients. Dr. Chbili’s research focuses on pharmacogenetics, pharmacokinetics, and the molecular mechanisms underlying drug efficacy and toxicity. She has contributed significantly to studies exploring the genetic determinants of drug metabolism, including investigations into glutathione-S-transferases in tuberculosis patients with drug-induced hepatotoxicity. Skilled in advanced laboratory techniques such as PCR, FISH, ELISA, and HPLC-MS, she has developed expertise in integrating molecular biology with clinical pharmacology. Dr. Chbili has authored 17 scientific documents, accumulated 138 citations across 123 indexed works, and maintains an h-index of 7, reflecting her impactful contributions to pharmacological and biomedical research in Tunisia and beyond.

Profiles: Scopus | Orcid | Research Gate

Featured Publications

Chbili, C., Mrad, S., Graiet, H., Selmi, M., Maatoug, J., Maoua, M., Abdellaoui, L., Mrizek, N., Nouira, M., Ben Fredj, M., et al. (2024). Randomized, placebo-controlled pilot study investigating the effects of Laurus nobilis tea on lipid profiles and oxidative stress biomarkers in healthy North African volunteers. The North African Journal of Food and Nutrition Research, 8(17), 86–98.

Chbili, C., Fathallah, N., Laadhari, C., Ouni, B., Saguem, S., Ben Fredj, M., Abdelghani, A., Ben Saad, H., & Ben Salem, C. (2022). Glutathione-S-transferase genetic polymorphism and risk of hepatotoxicity to antitubercular drugs in a North-African population: A case-control study. Gene, 808, 146019.

Rebai, A., Chbili, C., Ben Amor, S., Hassine, A., Ben Ammou, S., & Saguem, S. (2021). Effects of glutathione S-transferase M1 and T1 deletions on Parkinson’s disease risk among a North African population. Revue Neurologique, 177(1–2), 93–99.

Chbili, C. (2021, August 22). The effect of Origanum majorana tea on motor and non-motor symptoms in patients with idiopathic Parkinson’s disease: A randomized controlled pilot study. Journal article.

Chbili, C., Maoua, M., Selmi, M., Mrad, S., Khairi, H., Limem, K., Mrizek, N., Saguem, S., & Ben Fredj, M. (2020). Evaluation of daily Laurus nobilis tea consumption on lipid profile biomarkers in healthy volunteers. Journal of the American College of Nutrition, 39(6), 518–526.

Rebai, A., Reçber, T., Nemutlu, E., Chbili, C., Kurbanoglu, S., Kir, S., Ben Amor, S., Özkan, S. A., & Saguem, S. (2020). GC-MS based metabolic profiling of Parkinson’s disease with glutathione S-transferase M1 and T1 polymorphism in Tunisian patients. Combinatorial Chemistry and High Throughput Screening, 23(8), 785–794.

Georgia Kaiafa | Clinical Neuroscience | Best Researcher Award

Published on by Neuroscientists

Assoc. Prof. Dr. Georgia Kaiafa | Clinical Neuroscience | Best Researcher Award

Assoc. Prof. Dr. Georgia Kaiafa, Medical School, Aristotle University of Thessaloniki,  Greece.

Dr. Georgia Kaiafa is a distinguished hematologist and academician whose career spans clinical excellence, impactful research, and dedicated teaching. A graduate of Aristotle University of Thessaloniki, she earned her MBBS in 1987, Board Certification in Hematology in 1996, and completed her Doctorate in 2005. Her academic roles have progressed from Lecturer to Associate Professor of Hematology and Thromboembolic Diseases, with a longstanding association at AHEPA University Hospital.

Profile

Scopus

 

🎓 Early Academic Pursuits

Georgia Kaiafa began her academic journey in medicine at the prestigious Aristotle University of Thessaloniki, enrolling in the Medical School in 1980. Her foundational training was marked by determination and intellectual rigor, culminating in the completion of her MBBS in 1987. A steadfast commitment to advanced education led her to earn her Board Certification in Haematology by 1996, and later, she successfully defended her Doctorate thesis in 2005. These formative years reflect her deep-rooted passion for understanding hematological science and its clinical applications.

🧬 Professional Endeavors in Hematology

Her professional journey has been nothing short of inspiring, anchored in both clinical excellence and academic growth. Georgia Kaiafa has served in several academic ranks, beginning as a Lecturer in Hematology from 2007 to 2015, advancing to Assistant Professor until 2021, and currently holding the esteemed position of Associate Professor of Hematology and Thromboembolic Diseases. She is affiliated with AHEPA University Hospital’s Hematology Department, a major center of excellence in Greece. Her expertise was further enriched by her tenure as a Visiting Research Associate at King’s College Hospital in London in 2012, where she gained valuable international exposure. Since 2005, she has also played a leadership role as a Coordinator in the Northern Greece Office of the Health Sector, bridging academic medicine and healthcare policy.

🩸 Contributions and Research Focus

Georgia Kaiafa has devoted her scholarly efforts to advancing the understanding of thrombosis, thromboembolic disorders, and hematological malignancies. With her contributions to over 95 peer-reviewed international journal publications and participation as a Principal Investigator in 26 research trials, she has carved out a niche in evidence-based hematological research. Her investigations have deeply influenced protocols and practices in vascular pharmacology, hematologic diagnostics, and the clinical management of thrombotic conditions. She is also a prominent educator, mentoring Ph.D. candidates and contributing to postgraduate programs for both Greek and international students.

🏆 Accolades and Recognition

Her scientific contributions have not gone unnoticed. Georgia Kaiafa has received significant national acclaim, including the 1st Prize Award for Best Paper at the Pan-Hellenic Haematology Conference in 2008 and again at the 1st Conference of Internal Medicine of Northern Greece in 2015. These accolades affirm her research excellence and clinical insight. Her expertise has earned her memberships in elite national and international medical societies, including the Hellenic Stroke Organization and the European Stroke Organization, as well as a respected position in the Excellence of Thrombosis initiative.

🌍 Impact and Influence

Beyond academia and clinical service, Kaiafa has exerted influence on multiple scientific fronts. As a reviewer for prominent journals such as Thrombosis Research, Anemia, Case Reports in Hematology, and the Indian Heart Journal, she ensures high scientific standards in hematologic research worldwide. Her editorial work for both international and Greek journals demonstrates her authority in the field and her dedication to the progression of scientific communication. Her wide-ranging collaborations and committee leadership roles have significantly influenced health education and medical research in Greece and abroad.

📚 Scholarly Engagement and Mentorship

Georgia Kaiafa is not only a prolific researcher but also a passionate mentor and academic contributor. With 23 chapters in medical books, over 130 abstracts in Greek conference proceedings, and nearly 100 abstracts presented in international forums, her voice resonates across the global hematology community. She has mentored and supervised numerous doctoral students, serving on committees for 12 Ph.D. projects and directly supervising five, cultivating the next generation of scientific minds. She has also chaired 22 congress sessions and delivered more than 100 invited talks, emphasizing her respected role as both speaker and thought leader.

🔬 Legacy and Future Contributions

As a seasoned academic and clinical researcher, Georgia Kaiafa continues to shape the future of hematology in Greece and beyond. Her legacy lies in her dual commitment to clinical care and scientific discovery, especially in the realm of thromboembolic diseases and hematologic innovations. Her ongoing involvement in research protocols, editorial responsibilities, and student mentorship assures that her influence will persist. With a solid foundation and a career marked by excellence, her future contributions are likely to further impact hematological sciences and translational medicine globally.

publication

 

  • Title: Monocyte Chemoattractant Protein-1 as a Biomarker in Acute Ischemic Stroke: A Prospective Pilot Study
    Author(s): [Not specified]
    Year: 2025

 

  • Title: Prospective Study of ADAMTS13 and von Willebrand Factor’s Role in the Prediction of Outcomes in Acute Ischemic Stroke
    Author(s): [Not specified]
    Year: 2025

 

  • Title: Antiphospholipid Syndrome: A Comprehensive Clinical Review
    Author(s): [Not specified]
    Year: [Not specified]

 

  • Title: The Seasonal Distribution of Immune Thrombotic Thrombocytopenic Purpura is Influenced by Geography: Epidemiologic Findings from a Multi-Center Analysis of 719 Disease Episodes
    Author(s): [Not specified]
    Year: 2024

 

  • Title: Current Trends in Stroke Biomarkers: The Prognostic Role of S100 Calcium-Binding Protein B and Glial Fibrillary Acidic Protein
    Author(s): [Not specified]
    Year: [Not specified]

 

  • Title: Outpatient Management After Hospitalisation for Acute Decompensation of Cirrhosis: A Practical Guide
    Author(s): [Not specified]
    Year: 2024

 

  • Title: Which Is the Best Way to Treat Massive Hemoptysis? A Systematic Review and Meta-Analysis of Observational Studies
    Author(s): [Not specified]
    Year: [Not specified]

 

  • Title: Post-COVID-19 and Irritable Bowel Syndrome: A Literature Review
    Author(s): [Not specified]
    Year: [Not specified]

 

  • Title: Thyroid Disease and Systemic Lupus Erythematosus
    Author(s): [Not specified]
    Year: 2023

 

🏁 Conclusion

Dr. Georgia Kaiafa embodies the values of academic integrity, scientific advancement, and clinical leadership. Her commitment to both national healthcare development and international scientific collaboration sets her apart. With a strong foundation in research, education, and public health, she not only meets but exceeds the criteria for recognition through the Best Researcher Award. Her body of work stands as a testament to sustained excellence and future promise in hematology and related disciplines.

Liliana Elena Weimer | Clinical Neuroscience | Best Researcher Award

Published on by Neuroscientists

Dr. Liliana Elena Weimer | Clinical Neuroscience | Best Researcher Award

Dr.  Liliana Elena Weimer, Center For Global Health Istituto Superiore di Sanita’ Rome, Italy.

Dr. Liliana Elena Weimer is a highly accomplished physician and clinical researcher , where she has risen to the prestigious Level II “First Researcher” position. Her professional focus lies in clinical trials for infectious diseases, particularly HIV and Hepatitis C. She has played a critical role in major national and international research efforts, including collaborations with the U.S. Clinical Trials Group and leadership of the large-scale PITER cohort involving 25,000 HCV patients. She is known not only for her scientific contributions but also for her humanitarian efforts during the COVID-19 emergency. Among her recognitions is the 1st Prize at the 2019 International Congress on Hepatitis C in Seville. Throughout her career, she has exemplified scientific integrity, dedication, and service to public health.

Profile

Google Scholar

🎓 Early Academic Pursuits

Born on December 19, 1965, in Buenos Aires to Italian parents, Dr. Liliana Elena Weimer embraced her dual heritage and committed herself to a life in medicine and research. With Italian citizenship and deep academic determination, she laid the groundwork for her career by studying medicine, ultimately finding her professional home in Italy. Her academic path, though not fully detailed, clearly led her toward a focus on clinical medicine and infectious diseases, with her earliest professional roles marking the beginning of a lifelong engagement in public health and biomedical research. Her intellectual dedication and international roots later became an asset in global research collaborations.

🩺 Professional Endeavors

Dr. Weimer’s distinguished career spans over three decades at the Italian National Institute of Health (ISS), beginning in 1985. Starting as a dedicated clinical physician, she ascended to Level III researcher status by 1990 and continued to grow into higher ranks, culminating in her success in the national Art. 15 competition for the Level II “First Researcher” role in 2022, officially backdated to 2021. Throughout her tenure at ISS, she became a central figure within the Global Health Center in Rome. Known for her tireless commitment, she often described her career not simply as a job but as a “mission,” emphasizing both her personal and professional passion for making a difference in human health.

🧪 Contributions and Research Focus

Specializing in clinical trials, Dr. Weimer has coordinated and participated in numerous groundbreaking studies in HIV and Hepatitis C (HCV). Since the early 1990s, she has collaborated closely with renowned figures such as Prof. Giovanni Rossi, Prof. Stefano Vella, and Prof. Gianni Rezza, contributing to some of the most pivotal HIV antiretroviral therapy trials in history. Her research efforts extended to co-leading and organizing both national and international multicenter clinical trials. Notably, she has been at the forefront of the PITER study, a major nationwide cohort that follows 25,000 patients undergoing HCV treatment—one of the most comprehensive initiatives in Italy in the fight against hepatitis.

🌍 Global Collaborations and Humanitarian Engagement

Her impact extends beyond Italy, thanks to her active involvement with the U.S.-based American Clinical Trials Group on HIV studies. These collaborations have enhanced international understanding and treatment of HIV/AIDS. In addition to her clinical and research commitments, Dr. Weimer also devoted herself to frontline service during the COVID-19 pandemic. Volunteering both with the Civil Protection unit and at Bambino Gesù Children’s Hospital, she demonstrated profound humanitarian values. Her presence during a critical time underscored her belief in serving communities not just from behind a lab desk but also on the ground, directly supporting patients and health systems under strain.

🏅 Accolades and Recognition

Dr. Weimer’s work has been acknowledged at both national and international levels. One of the most prominent recognitions she received was the 1st Prize at the International Congress on Hepatitis C held in Seville in November 2019, a testament to her excellence and influence in the field of infectious disease research. Her achievements are not only measured in accolades but also in the tangible difference her work has made in advancing therapy options and clinical management of chronic viral diseases. Her rise within the ISS and the trust placed in her leadership of major research projects further affirm her standing within the scientific community.

💡 Impact and Influence

Over the course of her extensive career, Dr. Weimer has significantly shaped clinical research strategies in Italy, especially regarding chronic viral infections. Her coordination of thousands of patient cases within structured clinical trials has informed policy decisions and improved treatment protocols nationwide. Her presence at the ISS has also influenced future generations of researchers and clinicians, many of whom benefited from her mentorship, leadership, and example of scientific integrity. Through her rigorous methods and patient-focused approach, she has played a key role in Italy’s standing as a leader in global health research, especially in relation to HIV and HCV.

🔬 Legacy and Future Contributions

Looking forward, Dr. Weimer’s contributions will continue to echo through the fields of virology and clinical medicine. Her involvement in the PITER cohort and other studies has laid down essential groundwork for long-term epidemiological surveillance and patient care strategies. With her appointment as First Researcher, she enters a new chapter of leadership, likely to drive more innovative, patient-centered research initiatives in global health. Her legacy lies not only in her publications or awards but also in the thousands of lives improved by the treatments she helped to test, refine, and implement. The combination of scientific rigor and heartfelt service defines her enduring contribution to modern medicine.

Publication

  • Outcome of sustained virological responders with histologically advanced chronic hepatitis C – TR Morgan, MG Ghany, HY Kim, KK Snow, ML Shiffman, JL De Santo, … – 2010

 

  • Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5‐year follow‐up of 150 patients – SL George, BR Bacon, EM Brunt, KL Mihindukulasuriya, J Hoffmann, … – 2009

 

  • Safety and efficacy of simeprevir/sofosbuvir in hepatitis C–infected patients with compensated and decompensated cirrhosis – V Saxena, L Nyberg, M Pauly, A Dasgupta, A Nyberg, B Piasecki, … – 2015

 

  • Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy – D Persaud, SC Ray, J Kajdas, A Ahonkhai, GK Siberry, K Ferguson, … – 2007

 

  • Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real‐world cohort study – EB Tapper, BR Bacon, MP Curry, DT Dieterich, SL Flamm, LE Guest, … – 2016

 

  • Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with< 50 copies/ml HIV-1 RNA – S Baroncelli, CM Galluzzo, MF Pirillo, MG Mancini, LE Weimer, … – 2009

 

  • Predictors of failure with high-flow nasal oxygen therapy in COVID-19 patients with acute respiratory failure: a multicenter observational study – R Mellado-Artigas, LE Mujica, ML Ruiz, BL Ferreyro, F Angriman, E Arruti, … – 2021

 

  • A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients – M Floridia, R Bucciardini, D Ricciardulli, V Fragola, MF Pirillo, LE Weimer, … – 1999

 

  • Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohort – LA Kondili, F Romano, FR Rolli, M Ruggeri, S Rosato, MR Brunetto, … – 2017

 

  • Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER network – LA Kondili, GB Gaeta, D Ieluzzi, AL Zignego, M Monti, A Gori, A Soria, … – 2017

 

🏁 Conclusion

Dr. Weimer stands as a distinguished figure in the field of global health research, with deep expertise in clinical trials and infectious diseases. Her legacy is marked by landmark contributions to HIV and HCV treatment protocols, influential collaborations, and compassionate public service. Her ongoing work continues to shape public health policy and medical research in Italy and beyond. As she advances in her leadership role at the ISS, her experience, insight, and dedication will remain vital to future innovations in clinical research and global health.